An Immunobridging Study to Evaluate the Neutralizing Antibody Titer in Adults Immunized with Two Doses of Either ChAdOx1-nCov-19 (AstraZeneca) or MVC-COV1901

Rapid development and deployment of vaccines is crucial to control the continuously evolving COVID-19 pandemic. The placebo-controlled phase 3 efficacy trial is still the standard for authorizing vaccines in the majority of the world. However, due to a lack of eligible participants in parts of the w...

Descripción completa

Detalles Bibliográficos
Autores principales: Estrada, Josue Antonio, Cheng, Chien-Yu, Ku, Shin-Yen, Hu, Hui-Chun, Yeh, Hsiu-Wen, Lin, Yi-Chun, Chen, Cheng-Pin, Cheng, Shu-Hsing, Janssen, Robert, Lin, I-Feng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9146038/
https://www.ncbi.nlm.nih.gov/pubmed/35632411
http://dx.doi.org/10.3390/vaccines10050655

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9146038/
https://www.ncbi.nlm.nih.gov/pubmed/35632411
http://dx.doi.org/10.3390/vaccines10050655

Ejemplares similares